Loading...
•
Sep 30, 2021
Amicus Therapeutics Q3 2021 Earnings Report
Announced third quarter 2021 financial results and corporate updates.
Key Takeaways
Amicus Therapeutics announced its Q3 2021 financial results, featuring an 18% increase in total Galafold revenue compared to Q3 2020. The company is on track to complete the business combination of its gene therapy business with ARYA IV, resulting in the launch of Caritas Therapeutics.
Total Galafold revenue reached $79.5 million, marking an 18% increase compared to Q3 2020.
The company is reiterating its 2021 revenue guidance of $300 million to $315 million.
The FDA accepted the AT-GAA BLA and NDA for Pompe disease for review, and marketing authorization applications were submitted to the European Medicines Agency.
Amicus is on track to complete the planned business combination of its gene therapy business with ARYA IV, leading to the launch of Caritas Therapeutics in late 2021 or early 2022.
Revenue by Segment
Forward Guidance
Amicus Therapeutics is reiterating its 2021 revenue guidance of $300M-$315M
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...